Health Condition 1: C342- Malignant neoplasm of middle lobe,bronchus or lung Health Condition 2: null- Non-small cell lung cancer
Conditions
Interventions
None listed
Sponsors
AstraZeneca Pharma India Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients who provide written informed consent 2. Patients aged 18 years and older 3. Newly diagnosed patients with Metastatic (stage IV) NSCLC. 4. Histologically confirmed Adenocarcinoma NSCLC patients as per tissue biopsy and the sample sent for EGFR mutation analysis. 5. Patient should be naïve for any systemic treatment (i.e. no chemotherapy or EGFR-TKI) 6. Provision of a routine blood (plasma) sample The prescription of any medicinal product is clearly separated from the decision to include the subject in the study.
Exclusion criteria
Exclusion criteria: 1. Patient with any medical condition that, in the opinion of the investigator, would interfere with outcome of the study 2. Patient participating in any other interventional clinical study/trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determine the level of concordance between EGFR mutation status obtained by tissue and blood (plasma) based testing in terms of Overall Concordance, Sensitivity specificity Positive predictive value and negative predictive valueTimepoint: one day | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Determine the frequency of mutations on Exon 19,20 & 21 of EGFR gene (including mutation subtypes: exon 19 deletions and the L858R) among study patients as assessed by the plasma samples 2. Assess the frequency of T790M mutation among study patientsTimepoint: one day | — |
Countries
India
Contacts
Public ContactAmit Kumar
AstraZeneca Pharma India Ltd
Outcome results
None listed